CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade GlaxoSmithKline PLC - GSKl CFD

14.260
0.88%
0.040
Low: 14.095
High: 14.26
Market Trading Hours* (UTC) Open now
Closes on Tuesday at 16:30

Mon - Fri: 08:00 - 12:00 12:03 - 16:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.040
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.028007 %
Charges from borrowed part ($-1.12)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.028007%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.015829 %
Charges from borrowed part ($-0.63)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.015829%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency GBP
Margin 20%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

*Information provided by Capital.com

GSK plc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 14.13
Open* 14.095
1-Year Change* -15.04%
Day's Range* 14.095 - 14.26
52 wk Range 12.81-18.43
Average Volume (10 days) 10.55M
Average Volume (3 months) 169.95M
Market Cap 57.85B
P/E Ratio 14.25
Shares Outstanding 4.09B
Revenue 31.48B
EPS 0.99
Dividend (Yield %) 7.07714
Beta 0.56
Next Earnings Date Feb 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 30, 2023 14.130 0.145 1.04% 13.985 14.260 13.985
Jan 27, 2023 14.100 0.065 0.46% 14.035 14.215 14.035
Jan 26, 2023 14.025 0.040 0.29% 13.985 14.140 13.980
Jan 25, 2023 13.995 0.040 0.29% 13.955 14.040 13.920
Jan 24, 2023 13.930 -0.150 -1.07% 14.080 14.125 13.835
Jan 23, 2023 14.120 0.075 0.53% 14.045 14.170 14.040
Jan 20, 2023 14.035 -0.160 -1.13% 14.195 14.195 14.005
Jan 19, 2023 14.165 0.095 0.68% 14.070 14.215 14.025
Jan 18, 2023 14.130 -0.155 -1.09% 14.285 14.290 14.015
Jan 17, 2023 14.375 0.010 0.07% 14.365 14.400 14.275
Jan 16, 2023 14.375 0.150 1.05% 14.225 14.400 14.225
Jan 13, 2023 14.365 0.270 1.92% 14.095 14.415 14.095
Jan 12, 2023 14.325 0.205 1.45% 14.120 14.330 14.090
Jan 11, 2023 14.095 0.010 0.07% 14.085 14.245 14.065
Jan 10, 2023 14.110 0.115 0.82% 13.995 14.195 13.995
Jan 9, 2023 14.220 -0.085 -0.59% 14.305 14.320 14.100
Jan 6, 2023 14.285 0.095 0.67% 14.190 14.390 14.165
Jan 5, 2023 14.310 0.170 1.20% 14.140 14.375 14.140
Jan 4, 2023 14.430 -0.080 -0.55% 14.510 14.670 14.405
Jan 3, 2023 14.495 0.310 2.19% 14.185 14.675 14.185

GlaxoSmithKline PLC Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 27889 30186 30821 33754 34099 34114
Revenue 27889 30186 30821 33754 34099 34114
Cost of Revenue, Total 8898 9317 9572 10168 10890 11427
Gross Profit 18991 20869 21249 23586 23209 22687
Total Operating Expense 25291 26005 25335 26793 26316 27949
Selling/General/Admin. Expenses, Total 8859 9341 9408 10671 10717 10225
Research & Development 3468 3862 3726 4338 4603 4776
Depreciation / Amortization 41 45 44 64 76 101
Interest Expense (Income) - Net Operating 3664 2139 1839 -128 1220 1073
Unusual Expense (Income) 782 1666 1038 2051 -807 772
Other Operating Expenses, Total -421 -365 -292 -371 -383 -425
Operating Income 2598 4181 5486 6961 7783 6165
Interest Income (Expense), Net Non-Operating -628 -646 -602 -708 -432 -1317
Other, Net -31 -10 -84 -32 -383 594
Net Income Before Taxes 1939 3525 4800 6221 6968 5442
Net Income After Taxes 1062 3247 3921 5268 6388 5096
Minority Interest -150 -637 -423 -623 -639 -711
Net Income Before Extra. Items 912 2610 3498 4645 5749 4385
Net Income 912 1532 3623 4645 5749 4385
Income Available to Common Excl. Extra. Items 912 2610 3498 4645 5749 4385
Income Available to Common Incl. Extra. Items 912 1532 3623 4645 5749 4385
Dilution Adjustment 1.074 0
Diluted Net Income 913.074 1532 3623 4645 5749 4385
Diluted Weighted Average Shares 4909 4941 4971 5016 5038 5065
Diluted EPS Excluding Extraordinary Items 0.186 0.52823 0.70368 0.92604 1.14113 0.86575
Dividends per Share - Common Stock Primary Issue 0.8 0.8 0.8 0.8 0.8 0.8
Diluted Normalized EPS 0.32758 0.94697 0.85456 1.35566 0.9736 0.87285
Total Extraordinary Items -1078 125
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 7418 8092 9077 9527 9780
Revenue 7418 8092 9077 9527 9780
Cost of Revenue, Total 2411 2519 2822 3675 3645
Gross Profit 5007 5573 6255 5852 6135
Total Operating Expense 5725 6453 7139 8632 6979
Selling/General/Admin. Expenses, Total 2315 2498 2504 2908 2681
Research & Development 1077 1165 1169 1363 1154
Depreciation / Amortization 26 25 25 25 23
Unusual Expense (Income) -13 323 735 796 -385
Other Operating Expenses, Total -91 -77 -116 -135 -139
Operating Income 1693 1639 1938 895 2801
Interest Income (Expense), Net Non-Operating -175 -169 -190 -189 -203
Net Income Before Taxes 1518 1470 1748 706 2598
Net Income After Taxes 1260 1538 1368 930 2167
Minority Interest -187 -143 -200 -181 -365
Net Income Before Extra. Items 1073 1395 1168 749 1802
Net Income 1073 1395 1168 749 1802
Income Available to Common Excl. Extra. Items 1073 1395 1168 749 1802
Income Available to Common Incl. Extra. Items 1073 1395 1168 749 1802
Dilution Adjustment 0
Diluted Net Income 1073 1395 1168 749 1802
Diluted Weighted Average Shares 5037 5060 5060 5074 5068
Diluted EPS Excluding Extraordinary Items 0.21302 0.27569 0.23083 0.14762 0.35556
Dividends per Share - Common Stock Primary Issue 0.19 0.19 0.19 0.23 0.14
Diluted Normalized EPS 0.19873 0.25375 0.3419 0.22566 0.2717
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 16711 15907 16927 19491 20247 18674
Cash and Short Term Investments 4986 3911 3958 4786 6370 4335
Cash 1462 826 569 795 1762 1427
Short Term Investments 3524 3085 3389 3991 4608 2908
Total Receivables, Net 5917 5950 6322 7148 7264 8031
Accounts Receivable - Trade, Net 4679 4693 5185 5494 5562 6258
Total Inventory 5102 5557 5476 5947 5996 5783
Prepaid Expenses 335 308 330 316 359 315
Other Current Assets, Total 371 181 841 1294 258 210
Total Assets 59081 56381 58066 79692 80431 79103
Property/Plant/Equipment, Total - Net 10808 10860 11058 11314 11006 10672
Property/Plant/Equipment, Total - Gross 22164 21719 22488 22565 22313 21518
Accumulated Depreciation, Total -11356 -10859 -11430 -11251 -11307 -10846
Goodwill, Net 5965 5734 5789 10562 10597 10552
Intangibles, Net 18776 17562 17202 30955 29824 30079
Long Term Investments 1248 1101 1558 2151 3424 2214
Note Receivable - Long Term 886 875 816 893 858 935
Other Long Term Assets, Total 4687 4342 4716 4326 4475 5977
Total Current Liabilities 19001 26569 22491 24050 22148 23670
Accounts Payable 3596 3528 3645 4144 4357 4535
Accrued Expenses 6444 6929 8535 9111 9753 11186
Notes Payable/Short Term Debt 1426 765 4420 5020 1145 802
Current Port. of LT Debt/Capital Leases 2703 2060 1373 1898 2580 2799
Other Current Liabilities, Total 4832 13287 4518 3877 4313 4348
Total Liabilities 57957 56449 53706 68287 65844 64048
Total Long Term Debt 14661 14264 20271 23590 23425 20572
Long Term Debt 14620 14221 20227 22580 22538 19760
Capital Lease Obligations 41 43 44 1010 887 812
Deferred Income Tax 1934 1396 1156 3810 3600 3556
Minority Interest 3839 3557 -688 6952 6221 6287
Other Liabilities, Total 18522 10663 10476 9885 10450 9963
Total Equity 1124 -68 4360 11405 14587 15055
Common Stock 1342 1343 1345 1346 1346 1347
Additional Paid-In Capital 2954 3019 3091 3174 3281 3301
Retained Earnings (Accumulated Deficit) -3263 -4348 -8 6659 8884 10073
ESOP Debt Guarantee -286 -400 -161 -135 -195 -28
Unrealized Gain (Loss) 380 329 140 409 1302 383
Other Equity, Total -3 -11 -47 -48 -31 -21
Total Liabilities & Shareholders’ Equity 59081 56381 58066 79692 80431 79103
Total Common Shares Outstanding 4910.11 4957.95 4922.93 4953.23 5029.98 5031.81
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 18524 17566 18254 18674 28988
Cash and Short Term Investments 4817 3562 3514 4335 13977
Cash & Equivalents 4757 3503 3453 4274 10967
Short Term Investments 60 59 61 61 3010
Total Receivables, Net 7183 7507 8284 8346 8797
Accounts Receivable - Trade, Net 6492 6902 7697 7860 8300
Total Inventory 6216 6330 6244 5783 6003
Other Current Assets, Total 308 167 212 210 211
Total Assets 78079 77011 78689 79103 89689
Property/Plant/Equipment, Total - Net 10633 10589 10667 10672 10704
Goodwill, Net 10442 10435 10582 10552 10705
Intangibles, Net 29418 29333 30241 30079 30468
Long Term Investments 3755 3235 2818 2214 1739
Other Long Term Assets, Total 5307 5853 6127 6912 7085
Total Current Liabilities 20275 21387 22417 23670 24278
Payable/Accrued 14610 14267 15230 17554 17577
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 3172 5041 4869 3601 4102
Other Current Liabilities, Total 2493 2079 2318 2515 2599
Total Liabilities 63214 61634 63263 64048 73508
Total Long Term Debt 23047 20442 20736 20572 29226
Long Term Debt 23047 20442 20736 20572 29226
Deferred Income Tax 3566 3587 3666 3556 3668
Minority Interest 6145 6201 6322 6287 6451
Other Liabilities, Total 10181 10017 10122 9963 9885
Total Equity 14865 15377 15426 15055 16181
Common Stock 1346 1347 1347 1347 1347
Additional Paid-In Capital 3296 3299 3300 3301 3436
Retained Earnings (Accumulated Deficit) 10223 10731 10779 10407 11398
Total Liabilities & Shareholders’ Equity 78079 77011 78689 79103 89689
Total Common Shares Outstanding 5031.39 5031.68 5031.74 5031.81 5083.9
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 1062 2169 4046 5268 6388 5096
Cash From Operating Activities 6497 6918 8421 8020 8441 7952
Cash From Operating Activities 978 988 954 1231 1214 1195
Amortization 796 934 902 1103 1137 1182
Non-Cash Items 1641 3072 1406 2416 -305 1381
Cash Taxes Paid 1609 1340 1326 1512 1655 1291
Cash Interest Paid 732 781 766 895 864 786
Changes in Working Capital 2020 -245 1113 -1998 7 -902
Cash From Investing Activities -1269 -1443 -1553 -5354 2161 -1777
Capital Expenditures -2352 -2202 -1796 -2163 -2239 -2931
Other Investing Cash Flow Items, Total 1083 759 243 -3191 4400 1154
Cash From Financing Activities -6392 -6380 -6389 -1840 -10132 -7589
Financing Cash Flow Items -1687 -1475 -10660 -1453 -1950 -1401
Total Cash Dividends Paid -4850 -3906 -3927 -3953 -3977 -3999
Issuance (Retirement) of Stock, Net 15 -9 74 51 29 21
Issuance (Retirement) of Debt, Net 130 -990 8124 3515 -4234 -2210
Foreign Exchange Effects 283 -100 8 -82 -39 -29
Net Change in Cash -881 -1005 487 744 431 -1443
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 1260 2798 4166 5096 2167
Cash From Operating Activities 331 1623 4185 7952 2542
Cash From Operating Activities 361 1025 2011 2377 704
Non-Cash Items 433 570 1140 1381 634
Cash Taxes Paid 155 700 857 1291 213
Cash Interest Paid 95 439 486 786 85
Changes in Working Capital -1723 -2770 -3132 -902 -963
Cash From Investing Activities -48 -233 -1416 -1777 -3593
Capital Expenditures -354 -1015 -2299 -2931 -601
Other Investing Cash Flow Items, Total 306 782 883 1154 -2992
Cash From Financing Activities -1376 -3421 -4815 -7589 7973
Financing Cash Flow Items -391 -883 -1052 -1401 16
Total Cash Dividends Paid -946 -2097 -3048 -3999 -952
Issuance (Retirement) of Stock, Net 15 19 20 21 12
Issuance (Retirement) of Debt, Net -54 -460 -735 -2210 8897
Foreign Exchange Effects -35 -34 -21 -29 12
Net Change in Cash -1128 -2065 -2067 -1443 6934
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.5966 229134683 -34164923 2022-07-19 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.1517 129037070 1316706 2022-11-29 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.3264 95245653 977516 2023-01-01 LOW
Dodge & Cox Investment Advisor/Hedge Fund 1.9418 79502299 0 2022-02-27 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 1.2736 52145714 113556 2023-01-01 LOW
Silchester International Investors, L.L.P. Investment Advisor/Hedge Fund 1.269 51954188 12827890 2022-11-28 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 1.2107 49570121 -418206 2023-01-01 LOW
Columbia Threadneedle Investments (UK) Investment Advisor/Hedge Fund 0.9198 37659407 -1831852 2022-11-28 LOW
Schroder Investment Management Ltd. (SIM) Investment Advisor/Hedge Fund 0.8805 36048753 1255452 2023-01-01 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.8358 34220716 -131359 2023-01-01 LOW
Franklin Mutual Advisers, LLC Investment Advisor/Hedge Fund 0.763 31239940 2050203 2023-01-01 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5454 22328352 526606 2022-11-29 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.5138 21037527 -869474 2022-11-28 LOW
Jupiter Asset Management Ltd. Investment Advisor/Hedge Fund 0.4997 20457122 1270578 2022-11-28 LOW
Independent Franchise Partners LLP Investment Advisor 0.4733 19376797 6500373 2022-11-29 LOW
Aviva Investors Global Services Limited Investment Advisor/Hedge Fund 0.464 18995200 -674014 2023-01-01 LOW
GlaxoSmithKline Plc ESOP Corporation 0.4534 18564231 -20616012 2021-12-31 LOW
Capital Research Global Investors Investment Advisor 0.4355 17828669 -58801534 2022-11-29 LOW
Mondrian Investment Partners Ltd. Investment Advisor 0.4144 16967070 -246648 2022-11-29 LOW
Schweizerische Nationalbank Bank and Trust 0.413 16908425 -1156909 2022-11-28 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

GSK Company profile

GlaxoSmithKline PLC - GSK CFD

GlaxoSmithKline (GSK) is a global healthcare company focussed in pharmaceuticals, vaccine development and consumer healthcare products. 

The company began as an apothecary shop in London in 1715. Today, GlaxoSmithKline is headquartered in Brentford, England, with regional offices in the US and Singapore. GlaxoSmithKline’s primary listing is on the London Stock Exchange under the ticker symbol ‘GSK’. The GSK stock price in the form of  American depositary shares is listed on the New York Stock Exchange.   

GlaxoSmithKline’s pharmaceutical business covers a broad portfolio of medicines in respiratory, HIV, immuno-inflammation and oncology. The company has a leadership position in respiratory disease medicines. GlaxoSmithKline’s HIV business is managed through its unit ViiV Healthcare, with Pfizer and Shionogi as minority shareholders. 

In addition to respiratory and HIV treatments, the company has a portfolio of pharmaceutical products for the treatment of conditions such as lupus, urology and anti-infectives. 

Its Established Products Portfolio (EPP) includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business.

GlaxoSmithKline is actively researching the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.

GlaxoSmithKline is also one of the world’s largest vaccine companies with a portfolio of more than 20 vaccines. The company has 12 vaccine manufacturing sites around the world. One of its four global R&D centres is dedicated to mRNA technology.

GlaxoSmithKline’s consumer healthcare business has portfolio of brands that include Sensodyne, Parodontax, Polident, Advil, Voltaire, Panadol, Striven, Theraflu and Centrum across oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, mineral and supplements segments. GlaxoSmithKline is set to spin-off its consumer healthcare business into an independent company under the name ‘Haleon’.’

The company pays dividends on a quarterly basis, in July, October, January and April.
Follow the GlaxoSmithKline stock price live at Capital.com today.

Industry: Pharmaceuticals (NEC)

980 Great West Road
BRENTFORD
MIDDLESEX TW8 9GS
GB

Income Statement

  • Annual
  • Quarterly

People also watch

XRP/USD

0.40 Price
+2.080% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00392

Oil - Crude

77.46 Price
-0.650% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 0.03

Natural Gas

2.64 Price
-2.040% 1D Chg, %
Long position overnight fee -0.0489%
Short position overnight fee 0.0279%
Overnight fee time 22:00 (UTC)
Spread 0.005

US100

11,949.50 Price
+0.160% 1D Chg, %
Long position overnight fee -0.0184%
Short position overnight fee 0.0072%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading